Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience

Bekoz H., KARADURMUS N., PAYDAŞ S., TÜRKER A., Toptas T., Tuglular T. F., ...More

ANNALS OF ONCOLOGY, vol.28, no.10, pp.2496-2502, 2017 (SCI-Expanded) identifier

  • Publication Type: Article / Article
  • Volume: 28 Issue: 10
  • Publication Date: 2017
  • Doi Number: 10.1093/annonc/mdx341
  • Journal Name: ANNALS OF ONCOLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.2496-2502
  • Erciyes University Affiliated: Yes


Background: Reed-Sternberg cells of classical Hodgkin's lymphoma (cHL) are characterized by genetic alterations at the 9p24.1 locus, leading to over-expression of programmed death-ligand 1 and 2. In a phase 1b study, nivolumab, a PD-1-blocking antibody, produced a high response in patients with relapsed or refractory cHL, with an acceptable safety profile.